Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.

Olliges, Elisabeth; Bührlen, Bernhard; Fischer, Franz; Boesecke, Christoph; Kümmerle, Tim; Schneider, Jochen; Weidlich, Simon; Cordes, Christiane; Heiken, Hans; Stellbrink, Hans-Jürgen; Krznaric, Ivanka; Scholten, Stefan; Jensen, Björn Erik-Ole; Wolf, Eva; Ronel, Joram; Spinner, Christoph D; On Behalf Of The Dualis Study Group

doi:10.1080/09540121.2021.1916873

journal article

Titel:: Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Dokumenttyp:: Article; Journal Article
Autor(en):: Olliges, Elisabeth; Bührlen, Bernhard; Fischer, Franz; Boesecke, Christoph; Kümmerle, Tim; Schneider, Jochen; Weidlich, Simon; Cordes, Christiane; Heiken, Hans; Stellbrink, Hans-Jürgen; Krznaric, Ivanka; Scholten, Stefan; Jensen, Björn Erik-Ole; Wolf, Eva; Ronel, Joram; Spinner, Christoph D; On Behalf Of The Dualis Study Group
Abstract:: The DUALIS study demonstrated efficacy and safety of switching to dolutegravir plus ritonavir-boosted darunavir (DRV/r) (2DR) as compared to standard-of-care-therapy with two nucleoside reverse transcriptase inhibitors + DRV/r (3DR) in pretreated people living with HIV (PLWH), 48 weeks after switching. This DUALIS sub-study investigates health-related-quality-of-life (HrQoL) in this study-population. The Hospital Anxiety and Depression Scale (HADS) and the Medical Outcome Survey-HIV (MOS-HIV) were used assessing anxiety and depression symptoms, respectively HrQoL. Data were collected at baseline, 4, 24, and 48 weeks after randomization. Outcome scores were dichotomized and used as criteria in longitudinal models identifying differential developments. Odds ratios (ORs) with 95% confidence intervals (CIs) were computed as main measures of effects. ORs<1 indicate better results for HADS, and worse for MOS-HIV scores in the 2DR compared to 3DR group. In total, 263 subjects were randomized and treated (2DR n=131, 3DR n=132; median age 48 years). Significant different progressions could only be found for HADS-Depression scores (OR=.87, 95% CI: .78, .98, p=.02). While HADS-Depression scores decreased in the 2DR group, they increased in 3DR group. This sub-study showed no disadvantages regarding HrQoL in PLWH after switching to DTG+DRV/r. Considering lifelong requirements for antiretroviral medication, close attention to HrQL is required.
Zeitschriftentitel:: AIDS Care
Jahr:: 2022
Band / Volume:: 34
Heft / Issue:: 6
Seitenangaben Beitrag:: 698-707
Volltext / DOI:: doi:10.1080/09540121.2021.1916873
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/33896276
Print-ISSN:: 0954-0121
TUM Einrichtung:: 1298; Klinik und Poliklinik für Innere Medizin II, Gastroenterologie; Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
BibTeX